Products
Lupartumab Biosimilar Antibody-Drug Conjugate (LYPD3) for Research
Cat No.: GMP-Bios-ab-329
Pre-Made Lupartumab biosimilar, Whole mAb ADC, Anti-LYPD3 Antibody: Anti-C4.4A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-329-1mg | 1mg | |
| GMP-Bios-ab-329-10mg | 10mg | |
| GMP-Bios-ab-329-100mg | 100mg | |
| GMP-Bios-ab-329-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lupartumab biosimilar, Whole mAb ADC, Anti-LYPD3 Antibody: Anti-C4.4A therapeutic antibody |
| INN Name | Lupartumab |
| Target | LYPD3 |
| Format | Whole mAb ADC |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Bayer HealthCare |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Development Tech | na |
About target - LYPD3
1. Protein Ly6/PLAUR domain-containing protein 3
2. Gene LYPD3
3. Organism Homo sapiens (Human)
Function
Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.
